A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
Completed · Phase 3 · NCT06687980
Conditions: Lichen Simplex Chronicus
At a glance
- Research payments reported, 2025
- $299,850
- U.S. investigators named
- 12
- Sites paid
- 13
- Planned or actual enrollment
- 138
About the trial
- Sponsor
- Sanofi (with Regeneron Pharmaceuticals)
- Tested
- Dupilumab (drug), Placebo (drug)
- Dates
- Started 2024-11-25; completion 2026-09-02
- Results posted
- Not yet
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC. Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The follow-up duration after treatment will be 12 weeks. The number of visits will be 6.
From ClinicalTrials.gov, last updated 2026-09-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $299,850 in research payments for this study in 2025 (32 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sunil S. Dhawan, MD Dermatology · Fremont, CA
- Cheryl L. Effron, M.D. Specialist · Anaheim, CA
- Stephen J. Lockwood, MD Dermatology · Brandon, FL
- Gil Yosipovitch, MD Dermatology · Miami, FL
- David J. Cohen, MD Dermatology · Macon, GA
- Michael P. Sheehan, M.D. Dermatology · Columbus, IN
- James Allred, MD Dermatology · Franklin, KY
- Alice J. Watson, MD, MPH Dermatology · Boston, MA
- Jason M. Schoenfeld, M.D. Mohs Surgery · Philadelphia, PA
- Edward L. Lain, M.D. Dermatology · Austin, TX
- Mark S. Lee, M.D. Dermatology · San Antonio, TX
- Craig F. Teller, M.D. Dermatology · Bellaire, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Progressive Clinical Research $61,429
- Southern Clinical Research Center $46,683
- Office of Research Administration $40,824
- Clincove Inc $29,800
- Brigham and Women's Hospital, MA $24,425
- Skin Care Physicians of Georgia $22,239
- Equity Medical Llc $16,900
- Clinical Research Philadelphia Llc $16,100
- Palm Harbor Dermatology PA PAlm Harbor Dermatology PA Dba True Clinical Research $11,800
- Bellaire Dermatology Associates PA $10,800
- Center for Dermatology Clinical Research Inc $10,800
- Pflugerville Dermatology Clinical Research Center Inc $4,500
- Moore Clinical Research $3,550
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.